Carmustine (BCNU)

==General information==
Class/mechanism: Nitrosourea, alkylates DNA and RNA, inhibits several key enzymatic processes by carbamoylation of amino acids in proteins.Carmustine (BiCNU) package insert Carmustine (BiCNU) package insert (locally hosted backup)
Route: IV
Extravasation: vesicant/irritant
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias or the prescribing information. 
==Diseases for which it is established (work in progress)==
*Anaplastic glioma (FDA)
*Classical Hodgkin lymphoma (FDA)
*CNS carcinoma (FDA)
*Glioblastoma (FDA)
*Non-Hodgkin lymphomas (FDA)
**CNS lymphoma
**Diffuse large B-cell lymphoma
**HIV-associated lymphoma
**Indolent lymphoma
***Follicular lymphoma
**Mantle cell lymphoma
**Peripheral T-cell lymphoma
==Diseases for which is was used==
*Breast cancer
*Melanoma
*Multiple myeloma (FDA)
==Patient drug information==
*Carmustine (BiCNU) package insert
*Carmustine (BiCNU) patient drug information (Chemocare)Carmustine (BiCNU) patient drug information (Chemocare)
*Carmustine (BiCNU) patient drug information (UpToDate)Carmustine (BiCNU) patient drug information (UpToDate)
==History of changes in FDA indication==
*1977-03-07: Initial FDA approval 
*2007-08-17 (oldest label available at Drugs @ FDA): indicated as palliative therapy as a single agent or in established combination therapy with other approved chemotherapeutic agents in brain tumors: glioblastoma, brainstem glioma, medulloblastoma, astrocytoma, ependymoma, and metastatic brain tumors. (No supporting studies are cited)
*2007-08-17 (oldest label available at Drugs @ FDA): indicated as palliative therapy for multiple myeloma in combination with prednisone. (No supporting studies are cited)
*2007-08-17 (oldest label available at Drugs @ FDA): indicated as palliative therapy for Hodgkin’s Disease as secondary therapy in combination with other approved drugs in patients who relapse while being treated with primary therapy, or who fail to respond to primary therapy. (No supporting studies are cited)
*2007-08-17 (oldest label available at Drugs @ FDA): indicated as palliative therapy for Non-Hodgkin’s lymphomas as secondary therapy in combination with other approved drugs for patients who relapse while being treated with primary therapy, or who fail to respond to primary therapy. (No supporting studies are cited)
==History of changes in EMA indication==
*1974-04-23: EURD
==Also known as==
*Generic names: BCNU, bischloroethylnitrosourea, carmustin
*Brand names: Becenun, BiCNU, Carmubris, Leucerom, Nitrourean, Nitrumon
==References==
Category:Drugs
Category:Intravenous medications
Category:Irritant
Category:Vesicant
Category:Nitrosoureas
Category:Alkylating agents
Category:Anaplastic glioma medications
Category:Classical Hodgkin lymphoma medications
Category:CNS lymphoma medications
Category:Diffuse large B-cell lymphoma medications
Category:Follicular lymphoma medications
Category:Glioblastoma medications
Category:HIV-associated lymphoma medications
Category:Indolent lymphoma medications
Category:Mantle cell lymphoma medications
Category:Peripheral T-cell lymphoma medications
Category:Breast cancer medications (historic)
Category:Melanoma medications (historic) 
Category:Multiple myeloma medications (historic)
Category:FDA approved in 1977
Category:EMA approved in 1974